Assessment of Piperacillin-Tazobactam Population Pharmacokinetic Models in Neonates: An External Validation
Bhim Bahadur Chaudhari1, Jaya Shree Dilli Batcha2,3, Arun Prasath Raju2,3
1Department of Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India.
Insights
This study evaluated population pharmacokinetic (PopPK) models for piperacillin-tazobactam in neonates. The models by Cohen-Wolkowiez et al. and Li et al. showed good predictive performance, enhancing their clinical implementation for neonatal antibiotic therapy.
Area of Science:
- Pharmacology
- Neonatal Medicine
- Antibiotic Therapy
Background:
- Neonatal pharmacotherapy requires optimized drug dosing for improved outcomes.
- Piperacillin-tazobactam is crucial for treating severe neonatal infections.
- Limited validated population pharmacokinetic (PopPK) models exist for piperacillin-tazobactam in neonates.
Purpose of the Study:
- To externally evaluate existing PopPK models for piperacillin-tazobactam.
- To assess the predictive performance of these models in a neonatal intensive care unit (NICU) population.
- To determine the suitability of established PopPK models for clinical application in neonates.
Main Methods:
- Systematic literature review of Scopus, PubMed, and Embase to identify relevant PopPK models.
- External validation of identified models using clinical data from neonates treated with piperacillin-tazobactam.
- Assessment of model bias and precision using prediction-based metrics and individual predictions.
Main Results:
- Three PopPK models were identified for external evaluation.
- Data from 46 neonates (53 plasma samples) were used for model assessment.
- The PopPK models by Cohen-Wolkowiez et al. (piperacillin) and Li et al. (tazobactam) demonstrated good predictive accuracy.
Conclusions:
- The evaluated PopPK models for piperacillin and tazobactam showed strong predictive capabilities with low rMAPE and rRMSE.
- External validation enhances the credibility of these PopPK models for clinical use.
- These validated models can support optimized piperacillin-tazobactam dosing in neonatal intensive care.
Background And Objective:
Neonatal pharmacotherapy has gained attention from clinicians and regulatory agencies for optimizing the dosage of the drug which improves therapeutic outcomes in this special population. Piperacillin-tazobactam antibiotic is commonly used as a therapeutic option for treatment of severe infection in neonatal intensive care units. There are few population pharmacokinetic (PopPK) studies of piperacillin and tazobactam published for this specific population and which were not validated in other study settings. The aim of this study was to externally evaluate the published population pharmacokinetic models for piperacillin-tazobactam.
Methods:
A systematic review was conducted through Scopus, PubMed, and Embase databases to identify PopPK models. Clinical data collected in neonates treated with piperacillin-tazobactam were used for evaluation of these models. Various prediction-based metrics were used for assessing the bias and precision of PopPK models using individual predictions.
Results:
Three PopPK models were identified for external evaluation. A total of 53 plasma samples were collected from 46 neonates admitted in the neonatal intensive care unit. The PopPK models reported by Cohen-Wolkowiez et al. for piperacillin and Li et al. for tazobactam were able to predict well for our clinical data.
Conclusion:
The PopPK models by Cohen-Wolkowiez et al. and Li et al. predicted our data well for piperacillin and tazobactam with the lower relative median absolute predictive error (rMAPE) of 8.61% and 16.48% and relative root mean square error (rRMSE) of 0.01 and 0.03, respectively. External evaluation of the published PopPK models of piperacillin and tazobactam resulted in enhancing their credibility to be implemented in clinical practice.
Related Concept Videos
01:12Analysis of Population Pharmacokinetic Data
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
01:20Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
01:26Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
01:24One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation
On...